Piper Sandler Issues Pessimistic Forecast for CVS Health (NYSE:CVS) Stock Price

CVS Health (NYSE:CVS) had its price target lowered by Piper Sandler from $101.00 to $99.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has an “overweight” rating on the pharmacy operator’s stock. Piper Sandler’s price objective would indicate a potential upside of 38.70% from the company’s current price.

Other analysts have also issued research reports about the company. The Goldman Sachs Group upped their target price on CVS Health from $95.00 to $97.00 and gave the stock a “buy” rating in a report on Thursday, February 12th. Argus cut their price objective on CVS Health from $91.00 to $90.00 and set a “buy” rating for the company in a report on Wednesday, January 28th. Cantor Fitzgerald restated an “overweight” rating on shares of CVS Health in a report on Wednesday, December 10th. Mizuho increased their price target on shares of CVS Health from $88.00 to $95.00 and gave the company an “outperform” rating in a research note on Wednesday, December 10th. Finally, TD Cowen restated a “buy” rating on shares of CVS Health in a research note on Friday, March 13th. Twenty analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $94.95.

CVS Health Stock Up 1.8%

Shares of NYSE:CVS traded up $1.24 during mid-day trading on Tuesday, reaching $71.38. 1,390,316 shares of the stock were exchanged, compared to its average volume of 8,771,730. The stock’s 50 day simple moving average is $76.45 and its 200-day simple moving average is $77.76. CVS Health has a one year low of $58.35 and a one year high of $85.15. The company has a market cap of $90.80 billion, a P/E ratio of 51.71, a P/E/G ratio of 0.73 and a beta of 0.49. The company has a quick ratio of 0.63, a current ratio of 0.84 and a debt-to-equity ratio of 0.80.

CVS Health (NYSE:CVS) last released its earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 EPS for the quarter, beating the consensus estimate of $1.00 by $0.09. CVS Health had a return on equity of 11.31% and a net margin of 0.44%.The firm had revenue of $105.69 billion for the quarter, compared to analysts’ expectations of $103.67 billion. During the same quarter in the previous year, the business posted $1.19 EPS. The business’s quarterly revenue was up 8.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. As a group, equities research analysts predict that CVS Health will post 5.89 EPS for the current year.

Institutional Investors Weigh In On CVS Health

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in shares of CVS Health by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 120,709,530 shares of the pharmacy operator’s stock valued at $9,579,508,000 after acquiring an additional 1,824,424 shares during the last quarter. Capital World Investors raised its holdings in CVS Health by 2.1% in the 3rd quarter. Capital World Investors now owns 68,382,158 shares of the pharmacy operator’s stock valued at $5,155,380,000 after buying an additional 1,419,575 shares during the last quarter. State Street Corp raised its holdings in CVS Health by 2.1% in the 4th quarter. State Street Corp now owns 60,183,743 shares of the pharmacy operator’s stock valued at $4,776,182,000 after buying an additional 1,245,457 shares during the last quarter. Capital International Investors grew its holdings in CVS Health by 3.4% during the 4th quarter. Capital International Investors now owns 27,592,356 shares of the pharmacy operator’s stock worth $2,189,793,000 after acquiring an additional 900,153 shares during the last quarter. Finally, Invesco Ltd. increased its position in CVS Health by 3.2% in the 3rd quarter. Invesco Ltd. now owns 24,293,058 shares of the pharmacy operator’s stock valued at $1,831,454,000 after acquiring an additional 760,579 shares during the period. 80.66% of the stock is owned by institutional investors.

Trending Headlines about CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS plans to open roughly 60 stores in 2026 (traditional, Target-based and ~20 pharmacy-only sites) after years of net closures — a deliberate footprint reset intended to capture more pharmacy volume and improve retail margins. CVS to Grow Store Footprint This Year With 60 New Locations
• Positive Sentiment: CVS opened its first “apothecary‑style” pharmacy-only store in Chicago and plans nearly 20 similar sites focused on prescriptions and pharmacist care — a low‑capex format targeted at underserved neighborhoods that could raise pharmacy same‑store performance. CVS plans roughly 60 store openings in 2026 after years of net closures
• Positive Sentiment: CVS is cited as a leader in the growing chemotherapy‑at‑home services market — an expanding, higher‑margin care channel that supports long‑term services growth beyond retail pharmacy. Trends and Opportunities in the Chemotherapy-At-Home Services Market, 2026-2030
• Neutral Sentiment: Zacks highlights medical stocks that could beat earnings using its Earnings ESP tool — a useful signal for investors but not a direct company announcement; no specific CVS beat claim in the item. These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
• Neutral Sentiment: Local regulatory changes (e.g., a Tennessee reform bill) could allow some CVS pharmacies to remain open under new rules — positive operationally in specific markets but limited in overall impact. CVS could keep pharmacies open under Tennessee reform bill, local pharmacists say
• Negative Sentiment: CVS reached a proposed FTC settlement related to insulin pricing — a regulatory overhang that could involve concessions or payments and inject near‑term legal risk and headlines. Investors will watch the final terms and timing. CVS Health (CVS) Reaches Proposed FTC Settlement on Insulin Pricing

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.